CRISPR screen identifies a target to treat type 1 diabetes

CRISPR screen identifies a target to treat type 1 diabetes

Type 1 diabetes occurs when a person's own immune system destroys insulin-producing beta cells in the pancreas. In recent years, scientists have learned how to grow large volumes of replacement beta cells, but the researchers are still trying out many options to protect these cells against the immune attack. Researchers now have found an unusual strategy that eventually may help to guard such transplanted beta cells or to slow the original onset of the disease.

Research in mouse models and in human cells has shown that targeting a protein called renalase may protect beta cells against autoimmune attack by strengthening them against stress, says the co-senior author on a paper describing the work in Nature Metabolism.

The authors also demonstrated that an existing FDA-approved drug inhibits renalase and increases the survival of beta cells in those lab models.

The study joins a growing set of evidence suggesting that functional problems with beta cells themselves may help to trigger the autoimmune attack in type 1 diabetes, say the authors. "You might have genes that make the beta cell a little bit dysfunctional and more prone to becoming a target of the immune system," the co-senior author explains.

The authors launched a bold gamble to try inhibiting genes across the genome, one at a time, using a screening technique based on the CRISPR gene-editing method with a beta cell line from a "non-obese diabetic" (NOD) mouse that models type 1 diabetes. "Whole genome CRISPR screening is a powerful tool for new target discovery and we hoped that it would help us find any mutations that protect the beta cell," the other co-senior author says.

The CRISPR screen for surviving beta cells produced a dozen genes of interest. The most striking was the gene for renalase, which previous research had shown is associated with type 1 diabetes.

Next, the researchers created NOD mouse beta cells, some with the renalase gene functionally "knocked out" and some not. They transplanted these cells to NOD mice with autoimmune diabetes.

Intact beta cells died off--but the renalase knock-out cells survived. "This was a very black-and-white research model," the co-senior author comments. "If the cells aren't protected, they're gone."

The investigators then looked to see if the cells that lacked the renalase gene provoked a diminished response from T immune cells (which spearhead the autoimmune assault) in a dish. The scientists found that one type of T cell was less likely to attack these knockout cells than to attack normal beta cells.

But what was slowing this autoimmune assault? In earlier work to analyze beta cell survival, the authors had analyzed how the cells respond to a condition called endoplasmic reticulum (ER) stress. Now when the team tried three ways of introducing ER stress to mouse beta cells in a dish, the researchers saw that the renalase mutation was protecting against this condition.

In the next step, to see if the same mechanisms were at work in human cells, the team created human beta cells for similar tests in a dish. "Again, we saw that the renalase knockout protected cells against ER stress," the co-senior author says.

The functions of renalase are not well understood, but the authors knew that the protein is an enzyme (which often can be targeted by drug compounds) and that other scientists had produced a three-dimensional crystal structural map of the protein.

Wondering if this map would give clues to uncover a compound that could target renalase, the investigators noticed that renalase is very similar to another enzyme that is inhibited by existing drugs--including one drug known as pargyline that was approved by the Food & Drug Administration almost 60 years ago to treat hypertension.

Testing pargyline in their mouse transplant model, the researchers found that the drug protected beta cells extremely well, says the co-senior author. Studying it in the mouse beta cells themselves, the scientists demonstrated that pargyline indeed was protecting against ER stress. In experiments with human cells, pargyline also displayed a protective effect.

The authors hope to test pargyline in a pilot clinical trial to see if it slows the progress of new onset type 1 diabetes in a small number of patients. "Since it's FDA-approved and the drug is safe, this would be the best approach to test if the protection we observed in mice and human cells will hold true in people," the author remarks. If research results continue to be positive, their next goal will be to find industry backing to develop a small molecule drug that provides even better protection than pargyline.